Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
…
4,358€
-2,37%
Echtzeit-Aktienkurs Vanda Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Vanda Pharmaceuticals Inc. Aktie
Vanda Pharmaceuticals: Strategische Investitionen und Marktpotenzial im Fokus - Experten sehen 218 % Kurspotenzial
Quartalszahlen im Zeichen von Investitionen Vanda Pharmaceuticals (VNDA) blickt im ersten Quartal 2026 auf eine Phase der strategischen Marktexpansion zurück,…
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
…
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug By Investing.com
Vanda Pharmaceuticals stock surges after the FDA approves its new Bipolar I drug…
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
…
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of +78.85% and -2.78%, respectively, for the quarter ended December 2025. Do the…
Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
…
Vanda Pharmaceuticals: H.C. Wainwright hebt das Kursziel nach der FDA-Zulassung im Bereich der Reisekrankheit an - Experte sieht 168 % Kurspotenzial
Vanda Pharmaceuticals (VNDA) hat sich in der biopharmazeutischen Branche als Spezialist für Erkrankungen des zentralen Nervensystems und seltene Krankheiten etabliert.…
US FDA approves Vanda Pharmaceuticals’ motion sickness drug By Reuters
US FDA approves Vanda Pharmaceuticals’ motion sickness drug…
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold By Investing.com
Vanda Pharmaceuticals stock rises after FDA lifts partial clinical hold…
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
…
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the…
Vanda Pharmaceuticals: Net-Net Status Presents A Trading Opportunity
…
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
…
Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer By Reuters
Vanda Pharmaceuticals rejects Cycle Pharmas second takeover offer…
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda
Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
…
Court advances Vanda Pharmaceuticals patent case By Investing.com
Court advances Vanda Pharmaceuticals patent case…
Vanda Pharmaceuticals drops after Future Pak walks away
…
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
…
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…
Vanda Pharmaceuticals rejects sweetened bid from Future Pak
…
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
…
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents By Reuters
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents…
Vanda Pharmaceuticals: Fanapt Bipolar Win Doesnt Change Much
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Dyspepsia Drug Pipeline Insight Report 2024 Featuring Vanda Pharmaceuticals, Dong-A ST, and Dexa Medica Group
Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Dyspepsia - Pipeline Insight, 2024" report has been added to…